Paroxetine and congenital malformations: Meta-Analysis and consideration of potential confounding factors

Benjamin Bar-Oz, Thomas Einarson, Adrienne Einarson, Radinka Boskovic, Lisa O'Brien, Heli Malm, Anick Bérard, Gideon Koren

Research output: Contribution to journalArticlepeer-review

193 Scopus citations

Abstract

Background: Antidepressants have been commonly used by women of childbearing age. Recent studies suggest that paroxetine, a selective serotonin reuptake inhibitor (SSRI), might specifically increase teratogenic risk. Objectives: The purpose of this study was to quantify first-trimester exposure to paroxetine and birth defects and examine potential sources of bias in the in utero or postnatal detection of more congenital malformations among women with depression. We also sought to examine whether paroxetine was used for the same indications as other SSRIs among pregnant women. Methods: This meta-analysis was designed to quantify malformation rates associated with the use of paroxetine. A search of the literature from 1985 to 2006 (English language) found in MEDLINE, EMBASE, REPROTOX, Scopus, and Biological Abstracts was conducted using the following terms: pregnancy outcome, congenital or fetal AND anomalies, malformations, cardiac/heart defects, AND selective serotonin reuptake inhibitors, paroxetine, and Paxil. Administrative databases of medication and medical services use in the Province of Quebec, Canada, were used to calculate the rates of ultrasound and echocardiogram in pregnancy and infancy in women/infants exposed to SSRIs and to compare the indications for general SSRI use versus paroxetine use. Results: Based on the studies analyzed, first-trimester paroxetine exposure was associated with a significant increase in the risk for cardiac malformation (odds ratio [OR], 1.72; 95% CI, 1.22-2.42). Women using antidepressants in pregnancy had a 30% higher rate of utilization of ultrasound in pregnancy. Infants of women who received SSRIs underwent approximately twice as many echocardiograms in the first year of life compared with children of women who used nothing. Significantly more women receiving paroxetine used the drug for anxiety or panic than women receiving other SSRIs (OR, 4.11; 95% CI, 2.39-7.08). Conclusions: Based on the results of this metaanalysis, first-trimester exposure to paroxetine appears to be associated with a significant increase in the risk for cardiac malformation. However, a detection bias cannot be ruled out as contributing to the apparent increased detection of cardiovascular malformation of children exposed in utero to paroxetine. A significantly greater number of women were using paroxetine for anxiety or panic when compared with women using other SSRIs.

Original languageEnglish
Pages (from-to)918-926
Number of pages9
JournalClinical Therapeutics
Volume29
Issue number5
DOIs
StatePublished - May 2007
Externally publishedYes

Keywords

  • Paxil
  • cardiac malformations
  • congenital malformations
  • first trimester
  • paroxetine
  • selective serotonin reuptake inhibitors

Fingerprint

Dive into the research topics of 'Paroxetine and congenital malformations: Meta-Analysis and consideration of potential confounding factors'. Together they form a unique fingerprint.

Cite this